Evidence map›Paper›PMID 35157370›Full record

Trial reportClinical and translational science2022

Phase I and scintigraphy studies to evaluate safety, tolerability, pharmacokinetics, and lung deposition of inhaled GDC-0214 in healthy volunteers.

Rui Zhu, Hubert Chen, Joshua Galanter, Gaohong She, Fang Cai, Matthew R Durk, Yixuan Zou, Liuxi Chen, Jane R Kenny, Shweta Vadhavkar and 6 more

Open access · goldAbstract readClinical Trial, Phase IRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical and translational science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 2 countries.

Rui ZhuGenentech, Inc., South San Francisco, California, USA.
Hubert ChenGenentech, Inc., South San Francisco, California, USA.
Joshua GalanterGenentech, Inc., South San Francisco, California, USA.
Gaohong SheGenentech, Inc., South San Francisco, California, USA.
Fang CaiGenentech, Inc., South San Francisco, California, USA.
Matthew R DurkGenentech, Inc., South San Francisco, California, USA.
Yixuan ZouGenentech, Inc., South San Francisco, California, USA.
Liuxi ChenGenentech, Inc., South San Francisco, California, USA.
Jane R KennyGenentech, Inc., South San Francisco, California, USA.
Shweta VadhavkarGenentech, Inc., South San Francisco, California, USA.
Simon WarrenCardiff Scintigraphics, Cardiff, UK.
Glyn TaylorCardiff Scintigraphics, Cardiff, UK.
Olivia HwangGenentech, Inc., South San Francisco, California, USA.
Avi EliahuGenentech, Inc., South San Francisco, California, USA.
Chris WynneChristchurch Clinical Studies Trust (CCST; now New Zealand Clinical Research), Christchurch, New Zealand.
Ryan OwenGenentech, Inc., South San Francisco, California, USA.
Cardiff University · GBChristchurch Clinical Studies Trust · NZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several inflammatory cytokines that promote inflammation and pathogenesis in asthma signal through the Janus kinase 1 (JAK1) pathway. This phase I, randomized, placebo-controlled trial assessed the pharmacokinetics and safety of single and multiple ascending doses up to 15 mg twice daily for 14 days of a JAK1 inhibitor, GDC-0214, in healthy volunteers (HVs; n = 66). Doses were administered with a dry powder, capsule-based inhaler. An accompanying open-label gamma scintigraphy study in HVs examined the lung deposition of a single dose of inhaled Technetium-99m (

Indexed as

LungArea Under CurveDose-Response Relationship, DrugDouble-Blind MethodHealthy VolunteersHumansRadionuclide Imaging

Identifiers

PMID35157370
PMCPMC9099118
OpenAlexW4212890519

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.